The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells

Vandetanib, a multikinase inhibitor, is a target of drug treatments for non-small cell lung cancer (NSCLC). However, phase II and III clinical trials have not conclusively demonstrated the curative effects of vandetanib for NSCLC, and the reasons for this are unknown. In the present study, we use th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yan, Zhang, Yuanliang, Zou, Hanbing, Cai, Ning, Chen, Xiaojing, Xu, Longmei, Kong, Xianming, Liu, Peifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342569/
https://www.ncbi.nlm.nih.gov/pubmed/25720956
http://dx.doi.org/10.1038/srep08629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342569/
https://www.ncbi.nlm.nih.gov/pubmed/25720956
http://dx.doi.org/10.1038/srep08629

Ejemplares similares